8-K - Oncotelic Therapeutics, Inc. | StockGist

Current Report Details

Event Type

Material Agreement

Financing

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On December 31, 2025, Oncotelic Therapeutics, Inc. (the “Company” or “Our”) entered into an amendment to an independ

Material Agreement

$100.0M$45.0M

Source Document

2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant See Item 1.01, above. Item 9.01 Financial Stat

Financing

Exhibits (2)

10.1

EX-10.1

8-K